vs
Side-by-side financial comparison of LANDS' END, INC. (LE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
LANDS' END, INC. is the larger business by last-quarter revenue ($317.5M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs 1.6%, a 0.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 0.1%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -0.9%).
Lands' End, Inc. is an American retailer of clothing, baggage, and furniture which began as a mail-order yachting supply company in 1963 in Chicago. The company is named after Land's End; after promotional materials were printed, the founder noticed the typographical error in the location of the apostrophe, but could not afford to reprint the material. The company operates 26 domestic stores as of February 2024. Lands' End is headquartered in Dodgeville, Wisconsin.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LE vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $317.5M | $177.4M |
| Net Profit | $5.2M | $2.9M |
| Gross Margin | 51.8% | — |
| Operating Margin | 5.3% | 3.9% |
| Net Margin | 1.6% | 1.6% |
| Revenue YoY | 0.1% | 5.0% |
| Net Profit YoY | 198.3% | — |
| EPS (diluted) | $0.17 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $317.5M | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | $261.2M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | $318.6M | $187.3M | ||
| Q3 24 | $317.2M | $168.6M | ||
| Q2 24 | $285.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $5.2M | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $-8.3M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | $-593.0K | — | ||
| Q3 24 | $-5.3M | $-143.5M | ||
| Q2 24 | $-6.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 51.8% | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | 50.8% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | 50.6% | 78.7% | ||
| Q3 24 | 47.9% | 76.9% | ||
| Q2 24 | 48.7% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 5.3% | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | -0.9% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 2.9% | 13.2% | ||
| Q3 24 | 0.8% | -82.8% | ||
| Q2 24 | 0.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | -3.2% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | -0.2% | — | ||
| Q3 24 | -1.7% | -85.1% | ||
| Q2 24 | -2.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.17 | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $-0.27 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | $-0.02 | $0.38 | ||
| Q3 24 | $-0.17 | $-3.11 | ||
| Q2 24 | $-0.20 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $231.0M | $653.9M |
| Total Assets | $852.7M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $36.3M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | $18.1M | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $30.4M | $484.6M | ||
| Q3 24 | $25.6M | $453.8M | ||
| Q2 24 | $27.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $231.0M | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | $230.1M | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | $223.6M | $778.3M | ||
| Q3 24 | $226.5M | $749.6M | ||
| Q2 24 | $234.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $852.7M | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $760.5M | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $843.6M | $1.6B | ||
| Q3 24 | $802.5M | $1.5B | ||
| Q2 24 | $800.1M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | — |
| Free Cash FlowOCF − Capex | $-22.4M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | -3.03× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-55.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-15.7M | $43.7M | ||
| Q3 25 | — | $60.8M | ||
| Q2 25 | $-22.5M | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | $-17.1M | $33.1M | ||
| Q3 24 | $30.7M | $53.9M | ||
| Q2 24 | $-25.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-22.4M | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | $-30.7M | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $-27.8M | $31.0M | ||
| Q3 24 | $26.0M | $49.8M | ||
| Q2 24 | $-32.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | -11.8% | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | -8.7% | 16.6% | ||
| Q3 24 | 8.2% | 29.6% | ||
| Q2 24 | -11.4% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | 3.2% | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 3.3% | 1.1% | ||
| Q3 24 | 1.5% | 2.4% | ||
| Q2 24 | 2.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | -3.03× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LE
| U Se Commerce | $179.8M | 57% |
| Business Outfitters Revenue | $78.8M | 25% |
| Licensing And Retail | $20.2M | 6% |
| Other | $19.8M | 6% |
| Third Party | $18.9M | 6% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
